BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 19709563)

  • 1. [Dermatologic toxicity to sorafenib].
    Velázquez D; de la Cueva P; Zamberk P; Lázaro P
    Actas Dermosifiliogr; 2009; 100(6):518-20. PubMed ID: 19709563
    [No Abstract]   [Full Text] [Related]  

  • 2. Interstitial granulomatous drug reaction to sorafenib.
    Martínez-Morán C; Nájera L; Ruiz-Casado AI; Romero-Maté A; Espinosa P; Meseguer-Yebra C; Córdoba S; Borbujo JM
    Arch Dermatol; 2011 Sep; 147(9):1118-9. PubMed ID: 21931061
    [No Abstract]   [Full Text] [Related]  

  • 3. [Palmoplantar cutaneous reaction to sorafenib].
    Echeverría B; Llombart B; Botella-Estrada R; Guillén C
    Actas Dermosifiliogr; 2009 Oct; 100(8):736-7. PubMed ID: 19775561
    [No Abstract]   [Full Text] [Related]  

  • 4. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
    Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hand-foot-syndrome associated with medical tumor therapy - classification and management.
    Degen A; Alter M; Schenck F; Satzger I; Völker B; Kapp A; Gutzmer R
    J Dtsch Dermatol Ges; 2010 Sep; 8(9):652-61. PubMed ID: 20482685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe sorafenib-induced hand-foot skin reaction.
    Cuesta L; Betlloch I; Toledo F; Latorre N; Monteagudo A
    Dermatol Online J; 2011 May; 17(5):14. PubMed ID: 21635836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J; Escudier B; Wechsler J; Spatz A; Robert C
    Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib.
    Wolber C; Udvardi A; Tatzreiter G; Schneeberger A; Volc-Platzer B
    J Dtsch Dermatol Ges; 2009 May; 7(5):449-52. PubMed ID: 19178612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
    Lipworth AD; Robert C; Zhu AX
    Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
    McLellan B; Kerr H
    Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
    Risum S; Langer SW
    Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A man with blisters on hand and feet].
    Gelderblom AJ; van der Rhee JI; Ouwerkerk J
    Ned Tijdschr Geneeskd; 2011; 155(45):A3994. PubMed ID: 22085574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.
    Hütten M; Lassay L; Sachs B; Deutz P; Mertens R; Baron JM; Merk HF; Ott H
    Pediatr Dermatol; 2009; 26(3):349-50. PubMed ID: 19706105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acral lentiginosis associated with tegafur/gimeracil/oteracil (TS-1).
    Park YJ; Soh BW; Lee ES
    Eur J Dermatol; 2017 Apr; 27(2):209-210. PubMed ID: 28251899
    [No Abstract]   [Full Text] [Related]  

  • 15. Penile involvement with hand-foot syndrome.
    Sorscher SM
    Am J Clin Dermatol; 2004; 5(3):209-10. PubMed ID: 15186201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palisaded neutrophilic and granulomatous dermatitis in a rheumatoid arthritis patient after treatment with adalimumab.
    Umezawa Y; Ito K; Nakagawa H
    Eur J Dermatol; 2013; 23(6):910-1. PubMed ID: 24201093
    [No Abstract]   [Full Text] [Related]  

  • 17. Hand-foot and stump syndrome to sorafenib.
    Lai SE; Kuzel T; Lacouture ME
    J Clin Oncol; 2007 Jan; 25(3):341-3. PubMed ID: 17235051
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hand-foot syndrome and sorafenib].
    Milano G; Mortier L; Digue L; Desmedt E; Ravaud A
    Bull Cancer; 2009 Feb; 96(2):191-7. PubMed ID: 19258226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hand-foot syndrome.
    Pike K
    Oncol Nurs Forum; 2001; 28(10):1519-20. PubMed ID: 11759299
    [No Abstract]   [Full Text] [Related]  

  • 20. Imatinib-induced hand-foot syndrome in a patient with metastatic gastrointestinal stromal tumor.
    Battistella M; Frémont G; Vignon-Pennamen MD; Gornet JM; Dubertret L; Viguier M
    Arch Dermatol; 2008 Oct; 144(10):1400-2. PubMed ID: 18936416
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.